Standard Versus Extended Duration Direct-Acting Antiviral Therapy in Hepatitis C Patients With Slow Response to Treatment.
Conclusion and Relevance: Based on these findings, a recommendation for extension of therapy cannot be made for patients with detectable HCV RNA at week 4 of treatment at this time. Cost analyses may help guide recommendations to re-treat rare failures versus extend therapy in all slow responders.
PMID: 32406244 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - Category: Drugs & Pharmacology Authors: McKnight AH, Townsend ML, Hashem MG, Naggie S, Park LP, Britt RB Tags: Ann Pharmacother Source Type: research
More News: Antiviral Therapy | Cirrhosis | Drugs & Pharmacology | Hepatitis | Hepatitis C | Study | Virology